{"id":"optimal-medical-therapy-omt","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OMT is not a single drug entity but rather a standardized clinical protocol that typically includes evidence-based medications (such as beta-blockers, ACE inhibitors, statins, and antiplatelet agents) combined with lifestyle modifications. It is designed to optimize outcomes by individualizing therapy based on patient-specific factors, comorbidities, and disease severity. OMT serves as a control or comparator arm in clinical trials rather than an investigational therapeutic agent.","oneSentence":"Optimal Medical Therapy (OMT) is a comprehensive, guideline-based treatment approach that combines multiple pharmacological and lifestyle interventions tailored to individual patient characteristics.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:37.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coronary artery disease management (as a treatment protocol comparator)"},{"name":"Heart failure management (as a treatment protocol comparator)"}]},"trialDetails":[{"nctId":"NCT05838547","phase":"","title":"CANF-Comb-II PET-MR in Atherosclerosis Multisite","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-03-21","conditions":"Carotid Atherosclerosis, Asymptomatic Carotid Artery Stenosis, Carotid Artery Atheroma","enrollment":80},{"nctId":"NCT07454980","phase":"NA","title":"Pivotal Trial to Evaluate TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (The TRINITY Pivotal Trial)","status":"NOT_YET_RECRUITING","sponsor":"Jenscare Innovation Inc.","startDate":"2026-05","conditions":"Tricuspid Regurgitation (TR)","enrollment":680},{"nctId":"NCT07442526","phase":"","title":"AGECTO Study: PCI vs. Optimal Medical Therapy for CTO in the Octogenarian Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Luigi Gonzaga Hospital","startDate":"2025-07-01","conditions":"Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO), Percutaneous Coronary Intervention (PCI)","enrollment":200},{"nctId":"NCT04482062","phase":"NA","title":"TRISCEND II Pivotal Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edwards Lifesciences","startDate":"2021-04-09","conditions":"Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease","enrollment":864},{"nctId":"NCT05665608","phase":"NA","title":"Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-11-16","conditions":"Sudden Cardiac Death, Myocardial Infarction","enrollment":3595},{"nctId":"NCT05824520","phase":"NA","title":"Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-10-10","conditions":"Coronary Artery Disease, Myocardial Ischaemia","enrollment":1066},{"nctId":"NCT05599061","phase":"NA","title":"Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2023-01-30","conditions":"Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease","enrollment":600},{"nctId":"NCT04634266","phase":"NA","title":"TRICuspid Intervention in Heart Failure Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"LMU Klinikum","startDate":"2022-03-25","conditions":"Heart Failure Attributable to Severe Tricuspid Regurgitation","enrollment":360},{"nctId":"NCT04097145","phase":"NA","title":"Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial","status":"RECRUITING","sponsor":"Edwards Lifesciences","startDate":"2019-12-11","conditions":"Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease","enrollment":870},{"nctId":"NCT05810051","phase":"NA","title":"Exercise and Coronary Microvascular Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"CoreAalst BV","startDate":"2023-07-31","conditions":"Coronary Microvascular Disease","enrollment":204},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT03563417","phase":"NA","title":"ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO","status":"RECRUITING","sponsor":"Aarhus University Hospital Skejby","startDate":"2018-11-06","conditions":"Ischemic Heart Disease, Chronic Total Occlusion of Coronary Artery","enrollment":1560},{"nctId":"NCT06855537","phase":"PHASE4","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-03","conditions":"Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma","enrollment":2190},{"nctId":"NCT07254572","phase":"PHASE4","title":"Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2025-07-10","conditions":"Coronary Artery Disease, PreDiabetes","enrollment":300},{"nctId":"NCT06282042","phase":"NA","title":"Early Transcatheter Mitral Valve Repair After Myocardial Infarction","status":"RECRUITING","sponsor":"Fundación para la Investigación Biosanitaria del Principado de Asturias","startDate":"2024-12-24","conditions":"Acute Mitral Regurgitation","enrollment":250},{"nctId":"NCT03179774","phase":"NA","title":"Endovascular Revascularization for Chronic Carotid Artery Occlusion Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2017-05-17","conditions":"Carotid Occlusion","enrollment":200},{"nctId":"NCT06995586","phase":"NA","title":"Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","status":"NOT_YET_RECRUITING","sponsor":"Nicosia General Hospital","startDate":"2025-09-01","conditions":"Cardio-pulmonary Bypass, Cardiovascular Diseases, Omega-3 Polyunsaturated Fatty Acids","enrollment":108},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":"Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block","enrollment":50},{"nctId":"NCT06542653","phase":"","title":"Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-09-17","conditions":"Coronary Atheroscleroses","enrollment":258},{"nctId":"NCT06447740","phase":"NA","title":"Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-06-03","conditions":"Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial","enrollment":200},{"nctId":"NCT05292716","phase":"NA","title":"Mitral Regurgitation Treatment in Advanced Heart Failure","status":"RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2021-04-21","conditions":"Heart Failure, Mitral Regurgitation","enrollment":172},{"nctId":"NCT02841098","phase":"NA","title":"\" Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke \"","status":"COMPLETED","sponsor":"Centre Hospitalier St Anne","startDate":"2019-09-16","conditions":"Asymptomatic Carotid Artery Stenosis","enrollment":43},{"nctId":"NCT05623358","phase":"NA","title":"PHARM Optimal-HF Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2023-03-13","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":42},{"nctId":"NCT06458907","phase":"NA","title":"TRICAV-II Pivotal: TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation.","status":"NOT_YET_RECRUITING","sponsor":"P+F Products + Features USA Inc.","startDate":"2024-12","conditions":"Tricuspid Regurgitation, Tricuspid Valve Disease","enrollment":600},{"nctId":"NCT02932553","phase":"PHASE4","title":"BVS Implantation in Patients With Variant Angina and MODerate Coronary Artery Disease","status":"WITHDRAWN","sponsor":"Seung-Jung Park","startDate":"2017-04-19","conditions":"Angina Pectoris, Variant","enrollment":""},{"nctId":"NCT05018247","phase":"NA","title":"Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-05-04","conditions":"Ischemic Heart Disease","enrollment":14},{"nctId":"NCT03756870","phase":"NA","title":"Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-07-01","conditions":"Chronic Total Occlusion of Coronary Artery","enrollment":82},{"nctId":"NCT04540354","phase":"NA","title":"Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death","status":"WITHDRAWN","sponsor":"Helios Health Institute GmbH","startDate":"2021-02-01","conditions":"Myocardial Infarction, Heart Failure, Sudden Cardiac Death","enrollment":""},{"nctId":"NCT04540289","phase":"NA","title":"Personalised Risk scOre For Implantation of Defibrillators in Patients With Preserved LVEF>35% and a High Risk for Sudden Cardiac Death","status":"WITHDRAWN","sponsor":"Helios Health Institute GmbH","startDate":"2021-02-01","conditions":"Myocardial Infarction, Sudden Cardiac Death","enrollment":""},{"nctId":"NCT04688190","phase":"","title":"CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-11-01","conditions":"Mitral Regurgitation","enrollment":800},{"nctId":"NCT01985360","phase":"PHASE4","title":"ISCHEMIA-Chronic Kidney Disease Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01","conditions":"Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases","enrollment":777},{"nctId":"NCT04808661","phase":"NA","title":"EndovaScular Versus mediCaL mAnagement of Uncomplicated Type B Intramural heMatoma Trial (ESCLAIM)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-03-01","conditions":"Intramural Hematoma","enrollment":154},{"nctId":"NCT03071653","phase":"PHASE2","title":"Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study","status":"SUSPENDED","sponsor":"University of Cape Town","startDate":"2016-11-24","conditions":"Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy","enrollment":30},{"nctId":"NCT02328820","phase":"NA","title":"Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-10","conditions":"Coronary Artery Disease","enrollment":455},{"nctId":"NCT04597489","phase":"","title":"Fractional FLOw Reserve In Cardiovascular DiseAses","status":"COMPLETED","sponsor":"LinkCare GmbH","startDate":"2019-12-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":64045},{"nctId":"NCT02857309","phase":"NA","title":"Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure","status":"TERMINATED","sponsor":"Impulse Dynamics","startDate":"2014-02","conditions":"Heart Failure","enrollment":50},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63},{"nctId":"NCT02982057","phase":"PHASE3","title":"Non Culprit Lesion Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2015-01","conditions":"STEMI","enrollment":50},{"nctId":"NCT02985268","phase":"NA","title":"Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF","status":"WITHDRAWN","sponsor":"Montreal Heart Institute","startDate":"2016-12","conditions":"Functional Mitral Regurgitation, Heart Failure","enrollment":""},{"nctId":"NCT03383718","phase":"","title":"DSE vs. FFR in SCAD and BYSTANDER Lesions","status":"COMPLETED","sponsor":"Bajcsy-Zsilinszky Hospital","startDate":"2014-12-01","conditions":"Ischemic Heart Disease","enrollment":200},{"nctId":"NCT01132495","phase":"NA","title":"FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2010-05","conditions":"Coronary Artery Disease","enrollment":1170},{"nctId":"NCT00608140","phase":"PHASE3","title":"Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-03","conditions":"Mitral Valve Insufficiency, Heart Failure","enrollment":2},{"nctId":"NCT03300011","phase":"NA","title":"Ultrasonic Cardiogram Evaluate the Prognosis of Percutaneous Revascularization of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Southeast University, China","startDate":"2016-10-01","conditions":"Coronary Chronic Total Occlusion","enrollment":200},{"nctId":"NCT02571803","phase":"NA","title":"Dietary Intervention to Stop COronary Atherosclerosis in Computed Tomography","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2015-10","conditions":"Coronary Artery Disease","enrollment":180},{"nctId":"NCT00805311","phase":"PHASE4","title":"Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis","status":"TERMINATED","sponsor":"Russian Cardiology Research and Production Center","startDate":"2009-04","conditions":"Carotid Artery Stenosis, Atherosclerosis, Stroke","enrollment":400},{"nctId":"NCT02499250","phase":"NA","title":"Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients","status":"UNKNOWN","sponsor":"Navy General Hospital, Beijing","startDate":"2015-01","conditions":"Refractory Angina Pectoris","enrollment":30},{"nctId":"NCT01631409","phase":"","title":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","status":"WITHDRAWN","sponsor":"City Hospital No 40, Saint Petersburg, Russia","startDate":"2013-09","conditions":"Coronary Heart Disease (CHD)","enrollment":""},{"nctId":"NCT02044835","phase":"PHASE2, PHASE3","title":"The Evaluation Studies of Curative Effect of Fu-zheng-qu-zhuo Oral Liquid in Treatment of Ischemic Nephropathy","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2013-01","conditions":"Atherosclerotic Renal Artery Stenosis","enrollment":60},{"nctId":"NCT01508663","phase":"PHASE4","title":"The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-08","conditions":"Coronary Artery Disease","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Optimal Medical Therapy (OMT)","genericName":"Optimal Medical Therapy (OMT)","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Optimal Medical Therapy (OMT) is a comprehensive, guideline-based treatment approach that combines multiple pharmacological and lifestyle interventions tailored to individual patient characteristics. Used for Coronary artery disease management (as a treatment protocol comparator), Heart failure management (as a treatment protocol comparator).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}